HOWL — Werewolf Therapeutics Balance Sheet
0.000.00%
- $40.60m
- -$44.30m
- $1.89m
- 25
- 28
- 25
- 14
Annual balance sheet for Werewolf Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 92.6 | 158 | 129 | 134 | 111 |
Net Total Receivables | — | — | 6.93 | 1.35 | 0 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 92.9 | 161 | 140 | 138 | 113 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3.12 | 16.3 | 17.5 | 14.8 | 12.3 |
Other Long Term Assets | |||||
Total Assets | 96.4 | 179 | 160 | 175 | 127 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 5.28 | 11.9 | 24 | 19.4 | 15.2 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 7.18 | 26.5 | 37.9 | 63.5 | 53.5 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 89.2 | 153 | 122 | 111 | 73.4 |
Total Liabilities & Shareholders' Equity | 96.4 | 179 | 160 | 175 | 127 |
Total Common Shares Outstanding |